共 48 条
- [41] Real-world evidence comparison of the effectiveness of ustekinumab with anti-TNF or vedolizumab in ulcerative colitis: 1-year maintenance therapy results from the prospective, observational RUN-UC study (vol 18, p i1480, 2024)JOURNAL OF CROHNS & COLITIS, 2024, 18 (08) : 1357 - 1357Bokemeyer, B.
- [42] Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naive patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDOIBD-studyALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 58 (04) : 429 - 442Bokemeyer, BerndPlachta-Danielzik, Sandradi Giuseppe, RominaEfken, PhilippMohl, WolfgangKrause, ThomasHoffstadt, MartinEhehalt, RobertTrentmann, LeoSchweitzer, AxelJessen, PetraHartmann, PetraSchreiber, Stefan
- [43] Real-world data on sequential therapy in moderate-to-severe UC: Unveiling second-line strategies after anti-TNF failureJOURNAL OF CROHNS & COLITIS, 2024, 18 : I1828 - I1829Farkas, B.Borsos, M.Resal, T.Bacsur, P.Szepes, Z.Savarino, E. V.Bertin, L.Limdi, J. K.Sethi-Arora, K.Miheller, P.Vilmos, F.Castiglione, F.Bonacci, L.Lukas, M.Maharshak, N.Berman, G.Krznaric, Z.Wetwittayakhlang, P.Lakatos, P. L.Seidelin, J. B.Attauabi, M.Michalopoulos, G.Ribaldone, D. G.Kagramanova, A.Chashkova, E.Sarlos, P.Saibeni, S.Shitrit, A. B. G.Molnar, T.Farkas, K.
- [44] Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF,Vedolizumab or Ustekinumab: A Real-World Multicentre European StudyJOURNAL OF CROHNS & COLITIS, 2022, 16 (12) : 1882 - 1892Yanai, HenitKagramanova, AnnaKnyazev, OlegSabino, JoaoHaenen, ShanaMantzaris, Gerassimos J.Mountaki, KaterinaArmuzzi, AlessandroPugliese, DanielaFurfaro, FedericaFiorino, GionataDrobne, DavidKurent, TinaYassin, SharifMaharshak, NitsanCastiglione, Fabianade Sire, RobertoNardone, Olga MariaFarkas, KlaudiaMolnar, TamasKrznaric, ZeljkoBrinar, MarkoChashkova, ElenaMargolin, Moran LivneKopylov, UriBezzio, CristinaShitrit, Ariella Bar-GilLukas, MilanChaparro, MariaTruyens, MarieNancey, StephaneLobaton, TrianaGisbert, Javier P.Saibeni, SimoneBacsur, PeterBossuyt, PeterSchulberg, JulienHoentjen, FrankVigano, ChiaraPalermo, AndreaTorres, JoanaReves, JoanaKarmiris, KonstantinosVelegraki, MagdaliniSavarino, EdoardoMarkopoulos, PanagiotisTsironi, EftychiaEllul, PierreSuarez, Cristina CalvinoWeisshof, Roni
- [45] A real-world comparison of the effectiveness and safety of vedolizumab and anti-tumor necrosis factor therapies in early treatment initiation with first-line biological therapy in ulcerative colitis: Results from EVOLVEJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 119 - 120Mantzaris, G.Bressler, B.Kopylov, U.Bassel, M.Colby, C.Lopez, C.Saha, S.Kifnidi, C.Agboton, C.Adsul, S.Demuth, D.Luo, M.Wang, S.Yarur, A.
- [46] REAL-WORLD COMPARISON OF TOFACITINIB VERSUS USTEKINUMAB AMONG ULCERATIVE COLITIS PATIENTS WITH PRIOR ANTI-TUMOR NECROSIS FACTOR ALPHA AND ANTI-INTEGRIN TREATMENT FAILURE: A PROPENSITY SCORE-ADJUSTED ANALYSISGASTROENTEROLOGY, 2021, 160 (06) : S5 - S5Dalal, Rahul S.Mitri, JenniferGoodrick, HannahAllegretti, Jessica R.
- [47] Stay in class or switch out of class after anti-TNF failure in inflammatory bowel disease (IBD). Real-world data from a large district general hospitalJOURNAL OF CROHNS & COLITIS, 2020, 14 : S414 - S414Johnson, H.Vythilingam, S.McLaughlin, S.
- [48] PATTERNS OF ANTI-TNF ADOPTION AND DIFFUSION: REAL WORLD EVIDENCE FROM A 12-YEAR COHORT OF CROHN'S DISEASE AND ULCERATIVE COLITIS PATIENTS TREATED IN TERTIARY REFERAL MEDICAL CENTERS IN ISRAELVALUE IN HEALTH, 2018, 21 : S146 - S146Sergienko, R.Schwartz, D.Odes, S.Greenberg, D.